Healthcare
Live Price
Offline$2.05
+0.00% today
Window Change
+38.18%
Window
Jun 23, 2025 → May 14, 2026
Coverage: 226 bars · Jun 23, 2025 → May 14, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Orexo AB (publ) (ORXOY) is a Healthcare stock with a market cap of $71.83M and listed on OTC. The stock last traded around $2.04 and up 38.2% across the available one-year price window (Jun 23, 2025 → May 14, 2026). Baseline metrics include revenue growth of -95.6%, EPS growth of +36.5%, a dividend yield of 0.0%. What stands out right now is revenue -95.6%, EPS +36.5%, free cash flow +563.9% with operating margin -91.1% and ROIC -58.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ORXOY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ORXOY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ORXOY Max Drawdown
-49.51%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ORXOY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$565.0M
-9.5% YoY
FY Net Income
-$223.5M
-25.8% YoY
Free Cash Flow
-$281.8M
-56.1% YoY
Revenue Growth
-95.6%
EPS Growth
+36.5%
Gross Margin
-71.9%
Net Margin
-101.1%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 26M | 590M | 639M | 624M | 565M |
| Gross Profit | -55M | 518M | 550M | 522M | 486M |
| Operating Income | -346M | -140M | -110M | -214M | -225M |
| EBITDA | -285M | 13M | -22M | -74M | -141M |
| Net Income | -129M | -203M | -128M | -178M | -224M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 910M | 123M | 171M | 132M | 504M |
| Total Assets | 1.3B | 595M | 787M | 1.1B | 1.3B |
| Total Liabilities | 810M | 721M | 728M | 915M | 924M |
| Shareholder Equity | 489M | -126M | 59M | 194M | 350M |
| Total Debt | 491M | 476M | 474M | 540M | 551M |
| Net Debt | -419M | 353M | 303M | 407M | 46M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
229M
-46.2% YoY
Capital Expenditures
53M
-120.9% YoY
Free Cash Flow
282M
-56.1% YoY
Key ratios
Gross Margin
-71.9%
Operating Margin
-91.1%
Net Margin
-101.1%
ROE
-228.4%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.